GPP can be triggered by the initiation and withdrawal of various medications, in particular the withdrawal of corticosteroids, and by infections, stress, and other conditions. 1,5,6,10 Patients ...

前言银屑病也叫牛皮癣。虽然世界范围内，中国人的患病率是最低之一。但是，中国的患病总数仍有230万（95%CI：0.9-610万），居世界第三（全世界前7名排序为：美国、印度、中国、德国、巴西、法国、英国）[1]。银屑病因为有各种并发症，且提示心脑血管 ...

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...

New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...

The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...

"Vanda and AnaptysBio link for generalised pustular psoriasis therapy" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has ...

佩索利单抗）的上市申请，用于减少12岁及以上青少年（体重≥40 kg）和成人的泛发性脓疱型银屑病（Generalized Pustular Psoriasis，简称GPP）发作。

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...